JP2002508832A - 生体分子相互作用を検出するためのタンパク質断片相補性アッセイ - Google Patents
生体分子相互作用を検出するためのタンパク質断片相補性アッセイInfo
- Publication number
- JP2002508832A JP2002508832A JP53241098A JP53241098A JP2002508832A JP 2002508832 A JP2002508832 A JP 2002508832A JP 53241098 A JP53241098 A JP 53241098A JP 53241098 A JP53241098 A JP 53241098A JP 2002508832 A JP2002508832 A JP 2002508832A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- molecule
- fragment
- interaction
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003993 interaction Effects 0.000 title claims abstract description 100
- 238000001498 protein fragment complementation assay Methods 0.000 title abstract description 20
- 239000012634 fragment Substances 0.000 claims abstract description 254
- 102000004190 Enzymes Human genes 0.000 claims abstract description 135
- 108090000790 Enzymes Proteins 0.000 claims abstract description 135
- 230000000694 effects Effects 0.000 claims abstract description 76
- 230000004927 fusion Effects 0.000 claims abstract description 69
- 238000003556 assay Methods 0.000 claims abstract description 58
- 230000000295 complement effect Effects 0.000 claims abstract description 41
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 38
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 claims abstract description 23
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 claims abstract description 23
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 15
- 108010022394 Threonine synthase Proteins 0.000 claims abstract description 12
- 102000004419 dihydrofolate reductase Human genes 0.000 claims abstract description 12
- 210000004900 c-terminal fragment Anatomy 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 225
- 102000004169 proteins and genes Human genes 0.000 claims description 176
- 238000000034 method Methods 0.000 claims description 169
- 210000004027 cell Anatomy 0.000 claims description 120
- 238000012360 testing method Methods 0.000 claims description 57
- 230000027455 binding Effects 0.000 claims description 49
- 230000004850 protein–protein interaction Effects 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 34
- 238000012216 screening Methods 0.000 claims description 26
- 239000002299 complementary DNA Substances 0.000 claims description 22
- 230000006916 protein interaction Effects 0.000 claims description 19
- 230000003197 catalytic effect Effects 0.000 claims description 13
- 230000004001 molecular interaction Effects 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 238000013467 fragmentation Methods 0.000 claims description 10
- 238000006062 fragmentation reaction Methods 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 9
- 102000037865 fusion proteins Human genes 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 7
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 238000001415 gene therapy Methods 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 230000004186 co-expression Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 102000014914 Carrier Proteins Human genes 0.000 claims description 2
- 108091008324 binding proteins Proteins 0.000 claims description 2
- 230000031018 biological processes and functions Effects 0.000 claims description 2
- 108091006047 fluorescent proteins Proteins 0.000 claims description 2
- 102000034287 fluorescent proteins Human genes 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 108091006059 phosphorescent proteins Proteins 0.000 claims 3
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 108010047357 Luminescent Proteins Proteins 0.000 claims 1
- 102000006830 Luminescent Proteins Human genes 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002547 new drug Substances 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 abstract description 46
- 238000013461 design Methods 0.000 abstract description 24
- 229960001082 trimethoprim Drugs 0.000 abstract description 15
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 abstract description 15
- 230000004083 survival effect Effects 0.000 abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 230000001965 increasing effect Effects 0.000 abstract description 6
- 241001529936 Murinae Species 0.000 abstract description 3
- 230000005757 colony formation Effects 0.000 abstract description 3
- 210000004898 n-terminal fragment Anatomy 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 53
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 48
- 108020001096 dihydrofolate reductase Proteins 0.000 description 48
- 230000014509 gene expression Effects 0.000 description 47
- 108020004414 DNA Proteins 0.000 description 35
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 32
- 102000055025 Adenosine deaminases Human genes 0.000 description 32
- 239000000758 substrate Substances 0.000 description 31
- 238000001514 detection method Methods 0.000 description 24
- 230000012010 growth Effects 0.000 description 22
- 239000003814 drug Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 239000013598 vector Substances 0.000 description 17
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 14
- 238000011161 development Methods 0.000 description 14
- 210000003527 eukaryotic cell Anatomy 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 14
- 230000009466 transformation Effects 0.000 description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000018109 developmental process Effects 0.000 description 13
- 238000006384 oligomerization reaction Methods 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000013459 approach Methods 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 11
- 210000004962 mammalian cell Anatomy 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 10
- 238000009650 gentamicin protection assay Methods 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 101000908713 Homo sapiens Dihydrofolate reductase Proteins 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 9
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 9
- 229960002930 sirolimus Drugs 0.000 description 9
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000003053 toxin Substances 0.000 description 9
- 229930024421 Adenine Natural products 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 229960000643 adenine Drugs 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 238000006555 catalytic reaction Methods 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 7
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 108700020796 Oncogene Proteins 0.000 description 7
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 7
- 108010084455 Zeocin Proteins 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 6
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000008238 biochemical pathway Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- 101710123462 Bleomycin resistance protein Proteins 0.000 description 5
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 5
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 5
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 5
- 102000005720 Glutathione transferase Human genes 0.000 description 5
- 108010070675 Glutathione transferase Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 5
- 102000006601 Thymidine Kinase Human genes 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000007877 drug screening Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 210000001236 prokaryotic cell Anatomy 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001960 triggered effect Effects 0.000 description 5
- 229940075420 xanthine Drugs 0.000 description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 241000672609 Escherichia coli BL21 Species 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 108090000848 Ubiquitin Proteins 0.000 description 4
- 102000044159 Ubiquitin Human genes 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 229940126575 aminoglycoside Drugs 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000003570 cell viability assay Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 229940014144 folate Drugs 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000006151 minimal media Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000006152 selective media Substances 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 210000002105 tongue Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 101150075693 AK gene Proteins 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 101100091482 Caenorhabditis elegans rop-1 gene Proteins 0.000 description 3
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 3
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 3
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 3
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000007248 cellular mechanism Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000007398 colorimetric assay Methods 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000005558 fluorometry Methods 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 3
- 229940097277 hygromycin b Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000003157 protein complementation Methods 0.000 description 3
- 102200016476 rs1555198495 Human genes 0.000 description 3
- 102220061993 rs786202533 Human genes 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102100035634 B-cell linker protein Human genes 0.000 description 2
- 101710083670 B-cell linker protein Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000016362 Catenins Human genes 0.000 description 2
- 108010067316 Catenins Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- 238000010631 GST assay Methods 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010054278 Lac Repressors Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- 241000242677 Schistosoma japonicum Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 2
- 102220499981 Target of EGR1 protein 1_I114A_mutation Human genes 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 101150027964 ada gene Proteins 0.000 description 2
- 150000003838 adenosines Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 230000007247 enzymatic mechanism Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000007421 fluorometric assay Methods 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- 230000007498 myristoylation Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 102200044416 rs104894256 Human genes 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000010396 two-hybrid screening Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 2
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 2
- 238000001086 yeast two-hybrid system Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 1
- BFFPVEVGHKMWLT-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;3,7-dihydropurin-6-one Chemical compound O=C1NC=NC2=C1NC=N2.O=C1NC(N)=NC2=C1NC=N2 BFFPVEVGHKMWLT-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 101710170920 62 kDa protein Proteins 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 101100068321 Aequorea victoria GFP gene Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 230000010665 Enzyme Interactions Effects 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 101710091881 GTPase HRas Proteins 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000033640 Hereditary breast cancer Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000519695 Ilex integra Species 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 101100434310 Mus musculus Ada gene Proteins 0.000 description 1
- 101100278853 Mus musculus Dhfr gene Proteins 0.000 description 1
- 241000341511 Nematodes Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 1
- 108010035235 Phleomycins Proteins 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000231739 Rutilus rutilus Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 101710146343 Scaffold protein D13 Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241001441724 Tetraodontidae Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 208000035994 Yersinia pseudotuberculosis Infections Diseases 0.000 description 1
- 208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 101150030721 ata gene Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 230000017484 calcium-dependent cell-cell adhesion Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000010822 cell death assay Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 208000014014 cystic hygroma Diseases 0.000 description 1
- 208000003688 cystic lymphangioma Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008846 dynamic interplay Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000004265 eukaryotic small ribosome subunit Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
- 210000001990 heterocyst Anatomy 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229930190071 lycoside Natural products 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006491 negative regulation of transport Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002810 primary assay Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 238000003344 protein fragment complementation method Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 102200097790 rs121434486 Human genes 0.000 description 1
- 102200001732 rs267607052 Human genes 0.000 description 1
- 102220005360 rs41430445 Human genes 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000010399 three-hybrid screening Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. ある分子の別個の断片を再構成することを含む分子相互作用を検出する ための分子断片相補性アッセイであって、前記断片の再構成は他の分子プロセス から独立して、前記分子の各断片に融合された分子ドメインの相互作用によって 行われることを特徴とする分子断片相補性アッセイ。 2. (a) 適切なリポーター分子を選択するステップと、 (b) 断片化がリポーター機能の可逆的な消失になるように前記リポーター 分子の断片化を実行するステップと、 (c) 前記リポーター分子の断片を他の分子と個別に融合若しくは付着させ るステップと、次いで、 (d) 前記断片に融合している分子の相互作用を通して前記リポーター断片 を再会合させるステップと を含んでなる生体分子相互作用を検出するための方法。 3. 前記リポーター分子が多量体タンパク質であることを特徴とする請求項 2に記載の方法。 4. 前記リポーター分子が多量体酵素であることを特徴とする請求項2に記 載の方法。 5. 前記リポーター分子が多量体レセプターであることを特徴とする請求項 2に記載の方法。 6. 前記リポーター分子が多量体結合タンパク質であることを特徴とする請 求項2に記載の方法。 7. 前記リポーター分子が触媒分子であることを特徴とする請求項2に記載 の方法。 8. 前記リポーター分子がエネルギー転移分子であることを特徴 とするである請求項2に記載の方法。 9. 前記リポーター分子が蛍光タンパク質若しくはルミネセントタンパク質 若しくはリン光タンパク質であることを特徴とする請求項2に記載の方法。 10. 前記検出される分子が核酸若しくはリボザイムであることを特徴とす る請求項2に記載の方法。 11. 前記検出される分子が脂質若しくはオリゴ糖であることを特徴とする 請求項2に記載の方法。 12. 前記検出される分子がリガンドであることを特徴とする請求項2に記 載の方法。 13. 前記検出される分子が核酸であることを特徴とする請求項2に記載の 方法。 14. 前記検出される分子がペプチドであることを特徴とする請求項2に記 載の方法。 15. 前記検出される分子が炭水化物であることを特徴とする請求項2に記 載の方法。 16. 前記断片化が遺伝的操作、合成化学若しくは新規合成、光化学的若し くは酵素的開裂、及びタンパク分解若しくは加水分解化学からなる群から選択さ れた方法によって行われることを特徴とする請求項2に記載の方法。 17. リポーター分子断片の前記再会合が前記断片に融合若しくは付着した 分子によって実行されることを特徴とする請求項2に記載の方法。 18. a) i) 第1分子の第1断片と、 ii) 前記第1分子に相違するか若しくは同一である第2分子、 を含む第1融合産物を生成するステップと、 b) i) 前記第1分子の第2断片と、 ii) 前記第1分子若しくは第2分子に相違するか若しくは同一である第 3分子と、 を含む第2融合産物を生成するステップと、 c) 第1及び第2融合産物を相互に接触させるようにするステップと、 d) 第1分子の再結合した断片の会合によって再獲得された活性について試 験するステップであって、前記再会合が第2及び第3分子の相互作用によって仲 介されるステップと を含んでなる生体分子相互作用を試験するための方法。 19. 前記第2若しくは前記第3分子の少なくとも1つがタンパク質である ことを特徴とする請求項18に記載の方法。 20. 前記第2若しくは前記第3分子の少なくとも1つが酵素であることを 特徴とする請求項18に記載の方法。 21. 前記第2若しくは前記第3分子の少なくとも1つが核酸であることを 特徴とする請求項18に記載の方法。 22. 第1分子の断片が第2分子に融合しており、断片の会合が第1分子の 活性の再形成によって検出されるアッセイを含む方法。 23. (a) 1) 連合しているときにその断片が検出可能な活性を提示できる第1分 子の第1断片と、 2) (a)の1)の断片に結合できる第2分子と を含む第1融合生成物と、 (b) 1) 前記第1分子の第2断片と 2) (b)の(1)の断片に結合できる第3分子と を含む第2融合生成物と、 (c) (a)及び(b)の両方と からなるグループから選択された生成物を含む組成物。 24. 別個の分子に各々が融合している第1分子の相補的断片を含む組成物 。 25. 第1分子が、多量体タンパク質、多量体レセプター、多量体結合タン パク質、触媒性分子、エネルギー転移分子、蛍光若しくはルミネセント若しくは リン光タンパク質を含む群から選択されていることを特徴とする請求項24に記 載の組成物。 26. 第1分子が多量体酵素であることを特徴とする請求項24に記載の組 成物。 27. 第2及び第3分子が相互に結合できることを特徴とする請求項24に 記載の組成物。 28. (a) 1) 連合しているときに断片が検出可能な活性を提示できる第1分子の 断片と、 2) 第1分子の断片に融合している第2分子と を含む第1融合生成物と、 (b) 1) 前記第1分子の第2断片と、 2) 第2若しくは第3分子と を含む第2融合産物と、 (c) (a)及び(b)の両方と からなるグループから選択された生成物をコードする配列を含む、融合生成物を コードする核酸分子を含んでなる組成物。 29. 請求項24若しくは請求項28のいずれかに記載の組成物を含む宿主 細胞。 30. 請求項24若しくは請求項28のいずれかに記載の組成物の使用又は 請求項29に記載の宿主細胞の使用を含むアッセイ。 31. (a)連合しているときに断片が検出可能な活性を提示できる第1分 子の相補的断片、又は(b)第2若しくは第3分子からの2つのタンパク質−タ ンパク質相互作用ドメインの結合と連合した生体分子相互作用についての試験方 法であって、前記方法が 1) (a) 連合しているときに断片が検出可能な活性を提示できる第1分子の 第1断片と、 (b) 第1タンパク質−タンパク質相互作用ドメインと の融合を生成するステップ、 2) (a) 前記第1分子の第2断片と、 (b) 前記第1タンパク質−タンパク質相互作用ドメインに結合できる第 2タンパク質−タンパク質相互作用ドメインと の融合を生成するステップと、 3) 1)及び2)の融合を相互に接触させるようにするステップと、 4) 前記活性について試験するステップと を含んでなる方法。 32. 前記第1分子の断片の活性が断片の一部を変化させることによって制 御され、それらの連合する能力を増加若しくは低下させることを特徴とする請求 項1、2、18、22又は31のいずれか1つに記載の方法。 33. (a) 1) 連合しているときにその断片が検出可能な活性を提示できる(第1 )分子の第1断片と、 2) 第1タンパク質−タンパク質相互作用ドメインと を含んでなる第1融合生成物と、 (b) 1) 前記第1分子の第2断片と、 2) 前記第1タンパク質−タンパク質相互作用ドメインに結合できる第 2タンパク質−タンパク質相互作用ドメインと を含んでなる第2融合生成物と、 (c) (a)及び(b)の両方と を含む群から選択された生成物を含む組成物。 34. (a) 1) 連合しているときにその断片が検出可能な活性を提示できる分子の 第1断片と、 2) 第1タンパク質-タンパク質相互作用ドメインと を含んでなる第1融合生成合産物、或いは、 (b) 1) 前記分子の第2断片と、 2) 前記第1タンパク質−タンパク質相互作用ドメインに結 合できる第2タンパク質−タンパク質相互作用ドメインと を含んでなる第2融合生成物、或いは、 (c) (a)及び(b)の両方と の何れかをコードする配列を含む、融合生成物をコードする核酸分子を含んで なる組成物。 35. 請求項33又は請求項34のいずれかに記載の組成物を含む宿主細胞 。 36. 請求項33又は請求項34に記載のいずれかの組成物の使用又は請求 項35に記載の宿主細胞の使用を含むアッセイ。 37. PCAを実行することを含むタンパク質アッセンブリーの動態を検出 する方法。 38. 請求項1、2、18、22又は31のいずれか1つに記載の方法を含 む、タンパク質アッセンブリーの動態を検出する方法。 39. PCAを実行することを含むcDNAライブラリーをスクリーニング する方法。 40. 請求項1、2、18、22又は31のいずれか1つに記載の方法を含 む、cDNAライブラリーをスクリーニングするする方法。 41. 色素産生、蛍光産生、酵素的、又はその他の光学的に検出可能なシグ ナルを発生させることを特徴とする請求項1、2、18、22、31、39又は 40のいずれか1つに記載の方法。 42. シグナル発生システムの一部としてジヒドロ葉酸還元酵素が使用され ることを特徴とする請求項1、2、18、22、31、39又は40のいずれか 1つに記載の方法。 43. 請求項1、2、18、22、31、39又は40のいずれか1つに記 載のアッセイを実行することを含む2つ以上の相互作用ド メインの少なくとも1つの最小距離を決定する方法。 44. 請求項1、2、18、22、31、39又は40のいずれか1つに記 載の任意のアッセイを実行することを含む、分子複合体が2以上の相互作用ドメ インを含んでいるかどうかを決定する方法。 45. 前記第2及び第3分子の相互作用を誘発する他の少なくとも1つの分 子が存在することを特徴とする請求項1、2、18、22、31、39又は40 のいずれか1つに記載の方法。 46. 相互作用を仲介する少なくとも1つの他の分子の存在のために第1又 は第2分子の部分間での相互作用が存在することを特徴とする請求項39又は4 0のどちらかに記載の方法。 47. 化合物に対して、前記化合物の存在下でPCAを実行すること及び任 意の阻害と前記(化合物の)存在を相関させることを含むPCAにおける分子相 互作用を阻害する可能性をテストする方法。 48.(a) 酵素をコードする遺伝子を少なくとも2個の断片に分けること によって優勢選択を可能にする酵素からプローブタンパク質断片を合成するステ ップと、 (b) 相互作用について試験される1以上の分子との融合タンパク質を構成 するステップと、 (c) (b)で入手したタンパク質を1以上のプローブ断片と融合させるス テップと、 (d) 融合タンパク質を共発現させるステップと、 (e) 酵素活性の再構成を検出するステップと を含んでなる、生きている微生物及び/又は細胞におけるタンパク質−タンパ ク質相互作用を検出する方法。 49. 酵素がマウスジヒドロ葉酸還元酵素であることを特徴とす る請求項48に記載の方法。 50. 融合タンパク質が前記マウスジヒドロ葉酸還元酵素のNとC末端断片 を含むペプチドを有しており、GCN4ロイシンジッパー配列に融合されている ことを特徴とする請求項48に記載の方法。 51. 相補的融合タンパク質の共発現が試験タンパク質の相互への結合によ って触媒されることを特徴とする請求項48に記載の方法。 52. 新規薬物標的を同定するために請求項48に記載の方法を利用するこ とを特徴とする、タンパク質−タンパク質相互作用を誘発若しくは阻害する化合 物に対して組み合わせたライブラリーをスクリーニング又は高スループットスク リーニングする方法。 53. 標的が生物学的に活性なタンパク質である請求項52に記載の方法。 54. 前記生物学的に活性なタンパク質がレセプター、阻害剤、酵素又はイ オンチャネルを含む群から選択されることを特徴とする請求項53に記載の方法 。 55. (a) 適切なリポーター分子を選択するステップと、 (b) 前記リポーター分子の断片化を実行するステップと、 (c) 前記リポーター分子の断片を他の分子へ個別に融合若しくは付着させ るステップと、次いで、 (d) 前記断片に融合している分子の相互作用を通して前記リポーター断片 を再会合させるステップと を含んでなる生体分子相互作用を検出するための方法。 56. 前記第1分子が、多量体タンパク質、多量体レセプター、多量体結合 タンパク質、触媒性分子、エネルギー転移分子、蛍光若しくはルミネセント若し くはリン光タンパク質を含む群から選択されて いることを特徴とする請求項55に記載の組成物。 57. 前記第1分子が多量体酵素であることを特徴とする請求項55に記載 の組成物。 58. 遺伝子療法を実施する方法において、請求項2の方法を実施すること を含むステップ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2,196,496 | 1997-01-31 | ||
CA002196496A CA2196496A1 (en) | 1997-01-31 | 1997-01-31 | Protein fragment complementation assay for the detection of protein-protein interactions |
PCT/CA1998/000068 WO1998034120A1 (en) | 1997-01-31 | 1998-02-02 | Protein fragment complementation assays to detect biomolecular interactions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002508832A true JP2002508832A (ja) | 2002-03-19 |
JP4262778B2 JP4262778B2 (ja) | 2009-05-13 |
Family
ID=4159802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53241098A Expired - Fee Related JP4262778B2 (ja) | 1997-01-31 | 1998-02-02 | 生体分子相互作用を検出するためのタンパク質断片相補性アッセイ |
Country Status (10)
Country | Link |
---|---|
US (7) | US6270964B1 (ja) |
EP (2) | EP1605042A3 (ja) |
JP (1) | JP4262778B2 (ja) |
AT (1) | ATE301835T1 (ja) |
AU (1) | AU5850598A (ja) |
CA (1) | CA2196496A1 (ja) |
DE (1) | DE69831136T2 (ja) |
DK (1) | DK0966685T3 (ja) |
ES (1) | ES2247673T3 (ja) |
WO (1) | WO1998034120A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006518853A (ja) * | 2003-02-06 | 2006-08-17 | オデッセイ セラ, インコーポレイテッド | ハイスループットおよびハイコンテント・スクリーニングのための蛋白質断片の相補性アッセイ |
JP2007532132A (ja) * | 2004-04-12 | 2007-11-15 | オデュッセイ セラ インコーポレイテッド | 薬理学的プロファイリングのための蛋白−蛋白相互作用 |
JP2008513805A (ja) * | 2004-09-22 | 2008-05-01 | オデュッセイ セラ インコーポレイテッド | 新しい薬物リード及び、既知の薬物の新しい治療的用途を同定する方法 |
JP2010517945A (ja) * | 2007-02-05 | 2010-05-27 | パンバイオ・リミテツド | 均一インビトロfecアッセイ及び成分 |
Families Citing this family (203)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6897017B1 (en) * | 1997-01-31 | 2005-05-24 | Odyssey Thera Inc. | Vivo library-versus-library selection of optimized protein-protein interactions |
US20020064769A1 (en) * | 2000-10-05 | 2002-05-30 | Watson Michnick Stephen William | Dynamic visualization of expressed gene networks in living cells |
CA2196496A1 (en) * | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
US7306914B2 (en) * | 1997-01-31 | 2007-12-11 | Odyssey Thera Inc. | Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy |
US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
DK1801214T3 (da) | 1997-07-07 | 2011-01-24 | Medical Res Council | In vitro sorteringsfremgangsmåde |
US6333154B1 (en) * | 1997-12-04 | 2001-12-25 | Institut Pasteur | Bacterial multi-hybrid system and applications thereof |
US6828099B2 (en) * | 1998-02-02 | 2004-12-07 | Odyssey Thera Inc. | Protein fragment complementation assay (PCA) for the detection of protein-protein, protein-small molecule and protein nucleic acid interactions based on the E. coli TEM-1 β-Lactamase |
US7855167B2 (en) * | 1998-02-02 | 2010-12-21 | Odyssey Thera, Inc. | In vivo screening of protein-protein interactions with protein-fragment complementation assays |
US7166424B2 (en) * | 1998-02-02 | 2007-01-23 | Odyssey Thera Inc. | Fragments of fluorescent proteins for protein fragment complementation assays |
AU756617B2 (en) | 1998-07-28 | 2003-01-16 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Leptin-mediated gene-induction |
AU5143099A (en) * | 1998-07-30 | 2000-02-21 | Universite De Montreal | Protein fragment complementation assays for the detection of biological or drug interactions |
JP2002526756A (ja) * | 1998-09-24 | 2002-08-20 | デューク ユニバーシティ | 生細胞におけるタンパク質−タンパク質相互作用の測定方法 |
EP1117762A4 (en) | 1998-09-29 | 2004-02-25 | Gamida Cell Ltd | METHOD FOR CONTROLLING PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND PRECELLER CELLS |
US20040038317A1 (en) * | 1999-03-15 | 2004-02-26 | Kalobios, Inc. | Breakpoint fusion fragment complementation system |
US8148110B2 (en) | 1999-03-15 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by β-lactamase reporter fragment complementation |
DE60036942T2 (de) * | 1999-05-24 | 2008-08-07 | New England Biolabs, Inc., Beverly | Verfahren zur herstellung von getrennten, nicht-übertragbaren genen, welche befähigt sind ein aktives proteinprodukt zu exprimieren |
US20040096938A1 (en) * | 1999-05-24 | 2004-05-20 | Ming-Qun Xu | Method for generating split, non-transferable genes that are able to express an active protein product |
AU6045900A (en) * | 1999-05-25 | 2000-12-12 | Panorama Research, Inc. | Interaction-activated proteins |
US6673554B1 (en) * | 1999-06-14 | 2004-01-06 | Trellie Bioinformatics, Inc. | Protein localization assays for toxicity and antidotes thereto |
EP1194539A2 (en) * | 1999-06-25 | 2002-04-10 | Universität Zürich | Hetero-associating coiled-coil peptides and screening method therefor |
WO2001000866A1 (en) | 1999-06-26 | 2001-01-04 | Odyssey Pharmaceuticals, Inc. | An in vivo library-versus-library selection of optimized protein-protein interactions |
WO2001001137A1 (en) * | 1999-06-30 | 2001-01-04 | Children's Medical Center Corporation | Fusion protein and uses thereof |
AU6363900A (en) * | 1999-07-22 | 2001-02-13 | Children's Medical Center Corporation | Expression cloning using a tagged cdna library |
WO2001051629A2 (en) * | 2000-01-13 | 2001-07-19 | Panorama Research, Inc. | Circularly permutated, interaction-activated proteins |
WO2001053479A2 (en) * | 2000-01-24 | 2001-07-26 | Sangamo Biosciences, Inc. | Molecular switches ii |
WO2001060840A2 (en) * | 2000-02-14 | 2001-08-23 | Board Of Regents, The University Of Texas System | Complementation assay assessing protein solubility and folding |
US6727070B2 (en) | 2000-02-14 | 2004-04-27 | The Board Of Regents, The University Of Texas System | Protein/solubility folding assessed by structural complementation |
US6780599B2 (en) | 2000-05-12 | 2004-08-24 | Yale University | Methods of detecting interactions between proteins, peptides or libraries thereof using fusion proteins |
WO2001088168A2 (en) * | 2000-05-12 | 2001-11-22 | Odyssey Pharmaceuticals, Inc. | Mapping molecular interactions in plants with protein fragments complementation assays |
DE60112282T2 (de) * | 2000-05-22 | 2006-04-20 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Auf rezeptorgrundlage arbeitende screening-verfahren für protein wechselwirkungen |
WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
GB0022458D0 (en) * | 2000-09-13 | 2000-11-01 | Medical Res Council | Directed evolution method |
DE60239097D1 (de) * | 2001-03-02 | 2011-03-17 | Gpc Biotech Ag | Drei-hybrid-assaysystem |
DE10110449A1 (de) * | 2001-03-05 | 2002-09-19 | Lisa Wiesmueller | Testsystem zur Bestimmung von Genotoxizitäten |
US20020177217A1 (en) * | 2001-03-26 | 2002-11-28 | Massachusetts Institute Of Technology | Method for studying protein-protein interactions |
EP1392870B1 (en) * | 2001-05-09 | 2008-02-27 | Discoverx, Inc. | Screening for enzyme inhibitors |
DE60234131D1 (de) * | 2001-08-01 | 2009-12-03 | Cellomics Inc | Neue fusionsproteine und molekulare bindungsassays |
GB0118995D0 (en) * | 2001-08-03 | 2001-09-26 | Univ Wales Medicine | Detection of mutations in nucleic acids |
AU2007200686B2 (en) * | 2001-09-20 | 2011-07-14 | Immunex Corporation | Selection of cells expressing heteromeric polypeptides |
WO2003035887A1 (en) * | 2001-09-20 | 2003-05-01 | Immunex Corporation | Selection of cells expressing heteromeric polypeptides |
GB0127564D0 (en) | 2001-11-16 | 2002-01-09 | Medical Res Council | Emulsion compositions |
WO2003046176A2 (en) | 2001-11-26 | 2003-06-05 | Hybrigenics | Protein-protein interactions in human immunodeficiency virus |
IL152904A0 (en) * | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
EP1465982A4 (en) * | 2002-01-25 | 2006-06-07 | Gamida Cell Ltd | PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED |
US6936427B2 (en) * | 2002-02-08 | 2005-08-30 | Trellis Bioscience, Inc. | Real time detection of intermolecular interaction |
US7335478B2 (en) * | 2002-04-18 | 2008-02-26 | Kalobios Pharmaceuticals, Inc. | Reactivation-based molecular interaction sensors |
US7432063B2 (en) * | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
SE0200531D0 (sv) * | 2002-02-22 | 2002-02-22 | Avaris Ab | Novel biomolecular complexes, method for their production and use |
ATE377644T1 (de) * | 2002-03-25 | 2007-11-15 | Applera Corp | Systeme und verfahren zum nachweis der funktion nukleärer rezeptoren unter verwendung von reporterenzymmutanten komplementierungen |
WO2003093793A2 (en) * | 2002-05-01 | 2003-11-13 | Trellis Bioscience, Inc. | Binary or polynary targeting and uses thereof |
GB0214553D0 (en) * | 2002-06-25 | 2002-08-07 | Univ Leeds | Reporter module molecules having active ion channel activity |
US7662554B2 (en) * | 2002-10-09 | 2010-02-16 | The Trustees Of Boston University | Nucleic acid supported protein complementation |
US9740817B1 (en) | 2002-10-18 | 2017-08-22 | Dennis Sunga Fernandez | Apparatus for biological sensing and alerting of pharmaco-genomic mutation |
EP1590477B1 (en) | 2003-01-29 | 2009-07-29 | 454 Corporation | Methods of amplifying and sequencing nucleic acids |
GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
WO2005001115A2 (en) * | 2003-05-30 | 2005-01-06 | Odyssey Thera, Inc. | Monitoring gene silencing and annotating gene function in living cells |
US8048627B2 (en) | 2003-07-05 | 2011-11-01 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
US8346482B2 (en) | 2003-08-22 | 2013-01-01 | Fernandez Dennis S | Integrated biosensor and simulation system for diagnosis and therapy |
CA2541765A1 (en) | 2003-10-10 | 2004-10-01 | Promega Corporation | Luciferase biosensor |
GB0329353D0 (en) * | 2003-12-19 | 2004-01-21 | Amersham Biosciences Uk Ltd | Cytochrome C protein and assay |
WO2005077125A2 (en) * | 2004-02-11 | 2005-08-25 | Applera Corporation | Methods and compositions for detecting nucleic acids |
US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
AU2005250333A1 (en) * | 2004-04-16 | 2005-12-15 | Genentech, Inc. | Omi PDZ modulators |
AU2005250369A1 (en) * | 2004-05-18 | 2005-12-15 | Genentech, Inc. | M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein |
US8586294B2 (en) | 2004-05-18 | 2013-11-19 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of protein translocation by beta-galactosidase reporter fragment complementation |
US20090221440A1 (en) * | 2004-07-12 | 2009-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions related to identifying protein-protein interactions |
EP2336177A1 (en) | 2004-08-04 | 2011-06-22 | Amgen, Inc | Antibodies to DKK-1 |
US20060040338A1 (en) | 2004-08-18 | 2006-02-23 | Odyssey Thera, Inc. | Pharmacological profiling of drugs with cell-based assays |
WO2006030442A2 (en) | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
EP1797427A4 (en) * | 2004-09-22 | 2009-04-08 | Odyssey Thera Inc | METHOD FOR IDENTIFYING NEW MEDICAMENT LEADS AND NEW THERAPEUTIC USES OF KNOWN MEDICAMENTS |
US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
US20060094682A1 (en) | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
US20060160109A1 (en) * | 2004-11-22 | 2006-07-20 | Odyssey Thera, Inc. | Harnessing network biology to improve drug discovery |
US20070212677A1 (en) * | 2004-11-22 | 2007-09-13 | Odyssey Thera, Inc. | Identifying off-target effects and hidden phenotypes of drugs in human cells |
EP1828408A4 (en) * | 2004-12-04 | 2008-08-27 | Univ California Los Alamos Nat | PROTEIN-PROTEIN INTERACTION DETECTION SYSTEM USING FLUORESCENT PROTEIN MICRODOMANS |
US20060204999A1 (en) * | 2005-03-14 | 2006-09-14 | Stephen Macevicz | Detecting molecular complexes |
US8227572B2 (en) * | 2005-08-19 | 2012-07-24 | Commonwealth Scientific And Industrial Research Organisation | Arachnocampa luciferases |
JP2009513141A (ja) * | 2005-10-27 | 2009-04-02 | トラスティーズ オブ ボストン ユニバーシティ | タンパク質相補によるリアルタイムインビボ核酸検出 |
US20090220942A1 (en) * | 2005-10-27 | 2009-09-03 | Natalia Broude | Activated split-polypeptides and methods for their production and use |
GB0523954D0 (en) * | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US7601517B2 (en) | 2006-01-10 | 2009-10-13 | Stanford University | Split protein self complementing fragments, systems, and methods of use thereof |
CA2636855C (en) | 2006-01-11 | 2016-09-27 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
WO2008018905A2 (en) * | 2006-01-17 | 2008-02-14 | Cellumen, Inc. | Method for predicting biological systems responses |
US9359635B2 (en) | 2006-04-03 | 2016-06-07 | Promega Corporation | Permuted and nonpermuted luciferase biosensors |
US7695928B2 (en) | 2006-04-10 | 2010-04-13 | Genentech, Inc. | Disheveled PDZ modulators |
US20070254338A1 (en) * | 2006-04-24 | 2007-11-01 | Amgen Inc. | Method for making recombinant protein using complementation dependent DHFR mutants |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
EP3031918B1 (en) | 2006-05-11 | 2018-03-14 | Raindance Technologies Inc. | Microfluidic devices |
JP5406019B2 (ja) | 2006-05-17 | 2014-02-05 | セルーメン、インコーポレイテッド | 自動化組織分析のための方法 |
US8178654B2 (en) | 2006-05-23 | 2012-05-15 | Stanford University | Estrogen receptor intramolecular folding systems, estrogen receptor intramolecular folding sensors, methods of use thereof, methods of detecting ER ligands, and methods of detecting ER agonists and antagonists |
WO2008021123A1 (en) | 2006-08-07 | 2008-02-21 | President And Fellows Of Harvard College | Fluorocarbon emulsion stabilizing surfactants |
MX2009004464A (es) * | 2006-10-27 | 2009-11-02 | Univ Boston | Conjugados biomoleculares divididos, dirigidos para el tratamiento de enfermedades, malignidades y desordenes, y metodos para su produccion. |
EP2095119A2 (en) * | 2006-11-10 | 2009-09-02 | Cellumen, Inc. | Protein-protein interaction biosensors and methods of use thereof |
WO2008097559A2 (en) | 2007-02-06 | 2008-08-14 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
WO2008130623A1 (en) | 2007-04-19 | 2008-10-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US20090075313A1 (en) * | 2007-05-04 | 2009-03-19 | Stanford University | Split protein fragments, split protein systems, methods of making split protein systems, and methods of using split protein systems |
EP2177611B1 (en) | 2007-08-01 | 2013-11-20 | Japan Science and Technology Agency | Method for measurement of concentration of antigen |
WO2009026303A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
US8986997B2 (en) * | 2007-08-31 | 2015-03-24 | The Regents Of The University Of Michigan | Methods and compositions for increasing biological molecule stability |
TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
EP2210104A4 (en) * | 2007-11-01 | 2011-02-23 | Univ Arizona State | CELL-FREE PROCEDURE FOR DETECTING PROTEIN-LIGAND INTERACTIONS |
EP2220247A4 (en) | 2007-11-16 | 2011-10-26 | Nuvelo Inc | ANTIBODIES DIRECTED AGAINST LRP6 |
WO2009111073A2 (en) * | 2008-03-06 | 2009-09-11 | Odyssey Thera, Inc. | High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders |
WO2009142735A2 (en) | 2008-05-19 | 2009-11-26 | Promega Corporation | LUCIFERASE BIOSENSORS FOR cAMP |
EP2315629B1 (en) | 2008-07-18 | 2021-12-15 | Bio-Rad Laboratories, Inc. | Droplet libraries |
JP5739807B2 (ja) * | 2008-08-18 | 2015-06-24 | ディスカヴァーエックス コーポレイション | 受容体チロシンキナーゼアッセイ |
JP5954990B2 (ja) | 2008-11-03 | 2016-07-20 | モレキュラー・パートナーズ・アーゲーMolecular Partners Ag | Vegf−aレセプター相互作用を阻害する結合タンパク質 |
US9388406B2 (en) | 2008-11-17 | 2016-07-12 | Cornell University | System useful for reporting protein-protein interactions in the bacterial periplasm |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
WO2010111231A1 (en) | 2009-03-23 | 2010-09-30 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
US8871686B2 (en) | 2009-07-07 | 2014-10-28 | Agency For Science, Technology And Research | Methods of identifying a pair of binding partners |
US8524457B2 (en) | 2009-09-22 | 2013-09-03 | William Patterson | Method for the selection of specific affinity binders by homogeneous noncompetitive assay |
US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
EP2517025B1 (en) | 2009-12-23 | 2019-11-27 | Bio-Rad Laboratories, Inc. | Methods for reducing the exchange of molecules between droplets |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
CA2789425C (en) | 2010-02-12 | 2020-04-28 | Raindance Technologies, Inc. | Digital analyte analysis with polymerase error correction |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
MX2012011986A (es) | 2010-04-15 | 2013-03-05 | Amgen Inc | RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO. |
AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
WO2011143339A1 (en) | 2010-05-11 | 2011-11-17 | Promega Corporation | Mutant protease biosensors with enhanced detection characteristics |
US9290794B2 (en) | 2010-05-11 | 2016-03-22 | Promega Corporation | Mutant protease biosensors with enhanced detection characteristics |
US9562897B2 (en) | 2010-09-30 | 2017-02-07 | Raindance Technologies, Inc. | Sandwich assays in droplets |
AR083740A1 (es) | 2010-10-27 | 2013-03-20 | Amgen Inc | Anticuerpos dkk1 (dickkopf-1) y metodos de uso |
CA2818990C (en) | 2010-11-26 | 2021-06-15 | Molecular Partners Ag | Designed repeat proteins binding to serum albumin |
EP2673614B1 (en) | 2011-02-11 | 2018-08-01 | Raindance Technologies, Inc. | Method for forming mixed droplets |
US9150852B2 (en) | 2011-02-18 | 2015-10-06 | Raindance Technologies, Inc. | Compositions and methods for molecular labeling |
WO2012118903A2 (en) | 2011-03-01 | 2012-09-07 | Amgen Inc. | Bispecific binding agents |
EP2686688B1 (en) | 2011-03-17 | 2019-05-08 | Cernostics, Inc. | Systems and compositions for diagnosing barrett's esophagus and methods of using the same |
EP2702069A4 (en) | 2011-04-29 | 2015-04-29 | Janssen Biotech Inc | IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF |
EP2714970B1 (en) | 2011-06-02 | 2017-04-19 | Raindance Technologies, Inc. | Enzyme quantification |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
WO2013033080A1 (en) * | 2011-08-29 | 2013-03-07 | Wayne State University | Device and method for optimizing photobiological processes |
MX2014004027A (es) | 2011-10-14 | 2014-04-30 | Genentech Inc | Activadores de zimogeno. |
CA2858572C (en) | 2011-12-08 | 2023-01-17 | Amgen Inc. | Human lcat antigen binding proteins and their use in therapy |
CN104204192A (zh) | 2012-02-13 | 2014-12-10 | 加米达细胞有限公司 | 间充质干细胞调理的基质及其产生和使用方法 |
EP2825549B1 (en) | 2012-03-16 | 2018-10-10 | F. Hoffmann-La Roche SA | Engineered conformationally-stabilized proteins |
US9139863B2 (en) | 2012-03-16 | 2015-09-22 | Genentech, Inc. | Engineered conformationally-stabilized proteins |
IL307989A (en) | 2012-04-27 | 2023-12-01 | Novo Nordisk As | Human CD30 ligand antigen-binding proteins |
BR112014032316A2 (pt) | 2012-06-28 | 2017-06-27 | Molecular Partners Ag | proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
US20140271629A1 (en) | 2013-03-14 | 2014-09-18 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
SG11201507306VA (en) | 2013-03-15 | 2015-10-29 | Promega Corp | Activation of bioluminescence by structural complementation |
EP3683237A1 (en) | 2013-03-15 | 2020-07-22 | Amgen Inc. | Human pac1 antibodies |
WO2014144553A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
EP3094974B1 (en) | 2014-01-14 | 2019-02-27 | Asedasciences AG | Identification of functional cell states |
AU2015224552A1 (en) * | 2014-03-03 | 2016-09-15 | Novogy, Inc. | Reducing horizontal gene transfer of functional proteins |
WO2015192089A1 (en) | 2014-06-12 | 2015-12-17 | Axion Biosystems, Inc. | Multiwell microelectrode array with optical stimulation |
CN106605382B (zh) * | 2014-08-27 | 2020-11-06 | Lg 电子株式会社 | 在无线通信系统中的发送数据的方法及用于其装置 |
CN105406948B (zh) * | 2014-09-12 | 2020-03-06 | 中兴通讯股份有限公司 | 一种实现并行多用户数据传输的方法及主节点 |
WO2016040767A2 (en) | 2014-09-12 | 2016-03-17 | Amgen Inc. | Chrdl-1 epitopes and antibodies |
CA2963228C (en) * | 2014-10-01 | 2021-05-04 | Lg Electronics Inc. | Data transmission method in wireless communication system and device therefor |
US9942055B2 (en) * | 2015-02-12 | 2018-04-10 | Intel IP Corporation | Apparatus, system and method of multicast communication |
JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
MX2018007859A (es) | 2015-12-23 | 2018-11-09 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1. |
WO2017182437A1 (en) | 2016-04-18 | 2017-10-26 | Universität Innsbruck | Quantification of an interaction between a ras protein and a raf protein |
US10239891B2 (en) * | 2017-05-15 | 2019-03-26 | Indicator Systems International, Inc. | Compositions to detect remnant cancer cells |
WO2018026965A1 (en) | 2016-08-02 | 2018-02-08 | Isi Life Sciences, Inc. | Compositions and methods for detecting cancer cells in a tissue sample |
EP3497231B1 (en) * | 2016-08-08 | 2023-10-04 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Bacterial systems for analyzing ubiquitylated polypeptides |
WO2018060415A1 (en) | 2016-09-29 | 2018-04-05 | Universität Innsbruck | Full length kinase activity-conformation reporter |
AU2018206279B2 (en) | 2017-01-06 | 2020-09-03 | Abl Bio Inc. | Anti-alpha-syn antibody and use thereof |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
US10753942B2 (en) | 2017-05-15 | 2020-08-25 | Indicator Systems International, Inc. | Methods to detect remnant cancer cells |
JOP20190259A1 (ar) | 2017-05-31 | 2019-10-31 | Amgen Inc | بروتينات ربط مولد ضد مضادة لـ jagged1 |
WO2018237097A1 (en) | 2017-06-20 | 2018-12-27 | Amgen Inc. | METHOD OF TREATING OR REDUCING METABOLIC DISORDERS USING GASTRIC INHIBITING PEPTIDE RECEPTOR BINDING PROTEINS (GIPR) IN ASSOCIATION WITH GLP-1 AGONISTS |
CA3071852A1 (en) | 2017-08-04 | 2019-02-07 | Amgen Inc. | Method of conjugation of cys-mabs |
US11932846B2 (en) | 2017-08-08 | 2024-03-19 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Chloramphenicol resistant split protein and uses thereof |
WO2019225787A1 (ko) | 2018-05-24 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-b7-h3 항체 및 그 용도 |
EP4266058A3 (en) | 2018-07-06 | 2024-02-21 | The Regents of the University of Colorado, a body corporate | Genetically encoded system for constructing and detecting biologically active agents |
CN111198272B (zh) * | 2018-11-20 | 2023-09-08 | 香港理工大学深圳研究院 | 体外检测蛋白间相互作用的方法和检测试剂盒及其应用 |
MX2021006783A (es) | 2018-12-10 | 2021-07-15 | Amgen Inc | Transposasa de piggybac mutada. |
CA3153963A1 (en) * | 2019-09-09 | 2021-03-18 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of restoring lysosomal function of retinal pigment epithelial cells by activation of tfeb |
EP4054590A1 (en) | 2019-11-04 | 2022-09-14 | Amgen Inc. | Methods for treating leukemia |
CA3165802A1 (en) * | 2020-01-25 | 2021-07-29 | The Trustees Of The University Of Pennsylvania | Compositions for small molecule control of precise base editing of target nucleic acids and methods of use thereof |
US20230184765A1 (en) | 2020-04-17 | 2023-06-15 | Vyriad, Inc. | Detection assays for coronavirus neutralizing antibodies |
AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
WO2022060878A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for treating prostate cancer |
TW202233660A (zh) | 2020-10-30 | 2022-09-01 | 美商安進公司 | 過表現胰島素樣生長因子受體突變體以調節igf補充 |
CN112375775A (zh) * | 2020-11-16 | 2021-02-19 | 中南民族大学 | 一种基于片段化萤光素酶-dna嵌合体互补的发光体系、构建方法及其应用 |
IL302739A (en) * | 2020-11-17 | 2023-07-01 | Nerd Bio Llc | High-throughput drug screening methods |
WO2022232376A1 (en) | 2021-04-29 | 2022-11-03 | Amgen Inc. | Methods for reducing low molecular weight species of recombinantly-produced proteins |
CA3222782A1 (en) | 2021-06-10 | 2022-12-15 | Amgen Inc. | Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3 |
TW202328442A (zh) | 2021-09-10 | 2023-07-16 | 美商安進公司 | 平臺宿主對igf—培養基之適應 |
WO2023183231A1 (en) | 2022-03-21 | 2023-09-28 | Amgen Inc. | Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer |
WO2024064744A2 (en) * | 2022-09-20 | 2024-03-28 | Dna Twopointo, Inc. | Engineered split dhfr-based methods and systems for selecting cells that have stably acquired a heterologous polynucleotide |
WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
WO2024089297A1 (en) | 2022-10-28 | 2024-05-02 | Urban Joerg | Novel fluorescent and bioluminescent proteins and reporter systems for ratiometric measurement of luminescence |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
CA2068190C (en) | 1991-05-15 | 1996-12-17 | Microgenics Corporation | Methods and compositions for enzyme complementation assays using the omega region of beta-galactosidase |
US5585237A (en) | 1993-10-25 | 1996-12-17 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from recombinant DNA |
US5585245A (en) * | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
US5610015A (en) * | 1995-03-23 | 1997-03-11 | Wisconsin Alumni Research Foundation | System to detect protein-RNA interactions |
CA2196496A1 (en) * | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
US6872871B2 (en) * | 1998-02-02 | 2005-03-29 | Odyssey Thera Inc. | Mapping molecular interactions in plants with protein fragments complementation assays |
US6897017B1 (en) * | 1997-01-31 | 2005-05-24 | Odyssey Thera Inc. | Vivo library-versus-library selection of optimized protein-protein interactions |
US6294330B1 (en) * | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
US6828099B2 (en) * | 1998-02-02 | 2004-12-07 | Odyssey Thera Inc. | Protein fragment complementation assay (PCA) for the detection of protein-protein, protein-small molecule and protein nucleic acid interactions based on the E. coli TEM-1 β-Lactamase |
-
1997
- 1997-01-31 CA CA002196496A patent/CA2196496A1/en not_active Abandoned
-
1998
- 1998-02-02 AU AU58505/98A patent/AU5850598A/en not_active Abandoned
- 1998-02-02 US US09/017,412 patent/US6270964B1/en not_active Expired - Lifetime
- 1998-02-02 WO PCT/CA1998/000068 patent/WO1998034120A1/en active IP Right Grant
- 1998-02-02 JP JP53241098A patent/JP4262778B2/ja not_active Expired - Fee Related
- 1998-02-02 DK DK98901905T patent/DK0966685T3/da active
- 1998-02-02 ES ES98901905T patent/ES2247673T3/es not_active Expired - Lifetime
- 1998-02-02 DE DE69831136T patent/DE69831136T2/de not_active Expired - Lifetime
- 1998-02-02 EP EP05017291A patent/EP1605042A3/en not_active Withdrawn
- 1998-02-02 AT AT98901905T patent/ATE301835T1/de active
- 1998-02-02 EP EP98901905A patent/EP0966685B9/en not_active Expired - Lifetime
-
2000
- 2000-02-07 US US09/499,464 patent/US6428951B1/en not_active Expired - Lifetime
-
2002
- 2002-05-24 US US10/154,758 patent/US6929916B2/en not_active Expired - Fee Related
-
2003
- 2003-01-29 US US10/353,090 patent/US7160691B2/en not_active Expired - Fee Related
-
2007
- 2007-01-08 US US11/650,466 patent/US7989218B2/en not_active Expired - Fee Related
-
2011
- 2011-08-01 US US13/137,257 patent/US8192944B2/en not_active Expired - Fee Related
-
2012
- 2012-06-04 US US13/488,193 patent/US20130022999A1/en not_active Abandoned
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006518853A (ja) * | 2003-02-06 | 2006-08-17 | オデッセイ セラ, インコーポレイテッド | ハイスループットおよびハイコンテント・スクリーニングのための蛋白質断片の相補性アッセイ |
JP2013015525A (ja) * | 2003-02-06 | 2013-01-24 | Odyssey Thera Inc | ハイスループットおよびハイコンテント・スクリーニングのための蛋白質断片の相補性アッセイ |
JP2007532132A (ja) * | 2004-04-12 | 2007-11-15 | オデュッセイ セラ インコーポレイテッド | 薬理学的プロファイリングのための蛋白−蛋白相互作用 |
JP2011139710A (ja) * | 2004-04-12 | 2011-07-21 | Odyssey Thera Inc | 薬理学的プロファイリングのための蛋白−蛋白相互作用 |
JP4902527B2 (ja) * | 2004-04-12 | 2012-03-21 | オデュッセイ セラ インコーポレイテッド | 薬理学的プロファイリングのための蛋白−蛋白相互作用 |
JP2008513805A (ja) * | 2004-09-22 | 2008-05-01 | オデュッセイ セラ インコーポレイテッド | 新しい薬物リード及び、既知の薬物の新しい治療的用途を同定する方法 |
JP2010517945A (ja) * | 2007-02-05 | 2010-05-27 | パンバイオ・リミテツド | 均一インビトロfecアッセイ及び成分 |
Also Published As
Publication number | Publication date |
---|---|
AU5850598A (en) | 1998-08-25 |
US20070148682A1 (en) | 2007-06-28 |
US20030049688A1 (en) | 2003-03-13 |
US6929916B2 (en) | 2005-08-16 |
DK0966685T3 (da) | 2005-12-19 |
ES2247673T3 (es) | 2006-03-01 |
DE69831136T2 (de) | 2006-06-08 |
EP0966685A1 (en) | 1999-12-29 |
US6270964B1 (en) | 2001-08-07 |
US20040038298A1 (en) | 2004-02-26 |
US7989218B2 (en) | 2011-08-02 |
EP1605042A3 (en) | 2011-01-12 |
ATE301835T1 (de) | 2005-08-15 |
CA2196496A1 (en) | 1998-07-31 |
US20110287950A1 (en) | 2011-11-24 |
EP1605042A2 (en) | 2005-12-14 |
EP0966685B1 (en) | 2005-08-10 |
DE69831136D1 (de) | 2005-09-15 |
US7160691B2 (en) | 2007-01-09 |
WO1998034120A1 (en) | 1998-08-06 |
US20130022999A1 (en) | 2013-01-24 |
US6428951B1 (en) | 2002-08-06 |
US8192944B2 (en) | 2012-06-05 |
JP4262778B2 (ja) | 2009-05-13 |
EP0966685B9 (en) | 2006-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4262778B2 (ja) | 生体分子相互作用を検出するためのタンパク質断片相補性アッセイ | |
US6294330B1 (en) | Protein fragment complementation assays for the detection of biological or drug interactions | |
US7192739B2 (en) | Ligand-dependent protein splicing | |
US20080145315A1 (en) | Protein fragment complementation assays in whole animals applications to drug efficacy, adme, cancer biology, immunology, infectious disease and gene therapy | |
US20210214708A1 (en) | Engineered promiscuous biotin ligases for efficient proximity labeling | |
EP1027608B1 (en) | Protein fragment complementation assays | |
US7855167B2 (en) | In vivo screening of protein-protein interactions with protein-fragment complementation assays | |
US20040053388A1 (en) | Detection of protein conformation using a split ubiquitin reporter system | |
AU783091B2 (en) | Protein fragment complementation assays to detect biomolecular interactions | |
CA2279329C (en) | Protein fragment complementation assays to detect biomolecular interactions | |
EP1349943A2 (en) | Detection of protein conformation using a split ubiquitin reporter system | |
CA2244349A1 (en) | Protein fragment complementation assays for the detection of biological or drug interactions | |
AU2009200049A1 (en) | Protein Fragment Complementation Assays to Detect Bimolecular Interactions | |
Brazier | An investigation into the structural role of the CCR4-NOT complex in mRNA stability |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070925 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080208 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080325 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080520 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080819 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090113 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090210 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120220 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130220 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140220 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |